Current Atherosclerosis Reports

, Volume 9, Issue 5, pp 359–366

Rimonabant: The role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients

Authors

  • Christopher T. Dibble
  • Eli V. Gelfand
    • Cardiovascular Division, Department of MedicineBrigham and Women’s Hospital, TIMI Study Group
Article

DOI: 10.1007/s11883-007-0046-z

Cite this article as:
Dibble, C.T., Gelfand, E.V. & Cannon, C.P. Curr Atheroscler Rep (2007) 9: 359. doi:10.1007/s11883-007-0046-z

Abstract

Rimonabant is a selective blocker of the CB1 cannabinoid receptor that has been developed for treatment of abdominal obesity, dyslipidemia, and control of diabetes. Four randomized clinical trials have demonstrated that following 1 year of treatment, 20 mg/d of rimonabant is associated with greater weight loss and reduction in waist circumference compared with placebo. Therapy with rimonabant is associated with favorable changes in serum high-density lipoprotein and triglycerides, as well as with an improvement in glycemic control among obese type 2 diabetic patients. Rimonabant appears to be well tolerated, with the most common side effects being nausea, anxiety, and depressive symptoms. Rimonabant is a novel agent that has the potential to be a useful adjunct to lifestyle and behavior modification in treatment of abdominal obesity, dyslipidemia, and dysglycemia.

Copyright information

© Current Medicine Group LLC 2007